AIP
CPRX

Ahrens Investment Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Ahrens Investment Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$17 Buy
+1
New +$16 ﹤0.01% 1014
2022
Q3 		– Sell
-1
Closed – – 306
2022
Q2 		$0 Hold
1
– – ﹤0.01% 976
2022
Q1 		$0 Buy
+1
New +$7 ﹤0.01% 1041

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ahrens Investment Partners's CPRX Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2023: 1 share worth $17. The stake represents ﹤0.01% of the portfolio and ranks #1014 among its holdings. This is a return to the name: Ahrens Investment Partners previously reported a position in CPRX as recently as Q2 2022.

Ahrens Investment Partners first reported a position in CPRX in Q1 2022 and has held it in 3 quarters since. 259 funds tracked by Wall St. Rank hold CPRX as of Q1 2023.

  • Ahrens Investment Partners held 1 share of Catalyst Pharmaceutical worth $17 as of Q1 2023.
  • Catalyst Pharmaceutical was a new Ahrens Investment Partners position in Q1 2023.
  • Catalyst Pharmaceutical made up ﹤0.01% of Ahrens Investment Partners's portfolio in Q1 2023, its #1014 holding.
  • Ahrens Investment Partners first reported a position in Catalyst Pharmaceutical in Q1 2022 and has held it in 3 quarters since.
  • 259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.